{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:19:47Z","timestamp":1788779987828,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P50AR060772"],"award-info":[{"award-number":["P50AR060772"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Kidney Foundation Young Investigator Grant"},{"DOI":"10.13039\/100000062","name":"NIH NIDDK","doi-asserted-by":"publisher","award":["DK007199"],"award-info":[{"award-number":["DK007199"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The prescribing patterns of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the CKD population remain largely unknown.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Prescription of SGLT-2i was low in patients with CKD, particularly those without diabetes.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Younger Black men with a history of heart failure and cardiologist visit were associated with higher odds of SGLT-2i prescription.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease progression and mortality in patients with chronic kidney disease (CKD), regardless of diabetes status. However, the prescribing patterns of these novel therapeutics in the CKD population in real-world settings remain largely unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included adults with stages 3\u20135 CKD included in the Mass General Brigham (MGB) CKD registry in March 2021. We described the adoption of SGLT-2i therapy and evaluated factors associated with SGLT-2i prescription using multivariable logistic regression models in the CKD population, with and without diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 72,240 patients with CKD met the inclusion criteria, 31,688 (44%) of whom were men and 61,265 (85%) White. A total of 22,653 (31%) patients were in the diabetic cohort, and 49,587 (69%) were in the nondiabetic cohort. SGLT-2i prescription was 6% in the diabetic cohort and 0.3% in the nondiabetic cohort. In multivariable analyses, younger Black men with a history of heart failure, use of cardiovascular medications, and at least one cardiologist visit in the previous year were associated with higher odds of SGLT-2i prescription in both diabetic and nondiabetic cohorts. Among patients with diabetes, advanced CKD stages were associated with lower odds of SGLT-2i prescription, whereas urine dipstick test and at least one subspecialist visit in the previous year were associated with higher odds of SGLT-2i prescription. In the nondiabetic cohort, CKD stage, urine dipstick test, and at least one nephrologist visit in the previous year were not significantly associated with SGLT-2i prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this registry study, prescription of SGLT-2i was low in the CKD population, particularly among patients without diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0007862021","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T17:50:11Z","timestamp":1642614611000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":48,"title":["Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis"],"prefix":"10.34067","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-3183","authenticated-orcid":false,"given":"Min","family":"Zhuo","sequence":"first","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1570-1486","authenticated-orcid":false,"given":"Leo F.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-8460","authenticated-orcid":false,"given":"Sri Lekha","family":"Tummalapalli","sequence":"additional","affiliation":[{"name":"Division of Healthcare Delivery Science and Innovation, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Mount","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Nephrology, Department of Medicine, VA Boston Healthcare System and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.R.","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lucier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika L.","family":"Mendu","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1681\/ASN.2016010027","article-title":"Social determinants of racial disparities in CKD","volume":"27","author":"Norton","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12882-019-1260-y","article-title":"Development of an electronic health record-based chronic kidney disease registry to promote population health management","volume":"20","author":"Mendu","year":"2019","journal-title":"BMC Nephrol"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 annual data report: Epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2215\/CJN.07730719","article-title":"Sodium glucose cotransporter 2 inhibition heralds a call-to-action for diabetic kidney disease","volume":"15","author":"Tuttle","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"dc210529","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2215\/CJN.00060119","article-title":"Trends in quality of care for patients with CKD in the United States","volume":"14","author":"Tummalapalli","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"e1910704","DOI":"10.1001\/jamanetworkopen.2019.10704","article-title":"Quality of chronic kidney disease management in Canadian primary care","volume":"2","author":"Bello","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: An analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.mayocp.2020.12.038","article-title":"Barriers to ACEI\/ARB use in proteinuric chronic kidney disease: An observational study","volume":"96","author":"McCoy","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"1179546819839418","DOI":"10.1177\/1179546819839418","article-title":"Patterns of antihypertensive drug utilization among US adults with diabetes and comorbid hypertension: The National Health and Nutrition Examination Survey 1999\u20132014","volume":"13","author":"Gu","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7812\/TPP\/16-143","article-title":"End-stage renal disease outcomes among the Kaiser Permanente Southern California Creatinine Safety Program (Creatinine SureNet): Opportunities to reflect and improve","volume":"21","author":"Sim","year":"2017","journal-title":"Perm J"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"B29-20250825","doi-asserted-by":"crossref","article-title":"KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","author":"de Boer","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"B30-20250825","first-page":"92","article-title":"Trends in utilization and cost of low-density lipoprotein cholesterol-lowering therapies among Medicare beneficiaries: An analysis from the Medicare Part D database","volume":"6","author":"Sumarsono","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"e21420","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"key":"B32-20250825","doi-asserted-by":"crossref","first-page":"e2020969","DOI":"10.1001\/jamanetworkopen.2020.20969","article-title":"Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the Medicare Part D program","volume":"3","author":"Luo","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B33-20250825","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dom.14268","article-title":"Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States","volume":"23","author":"Reifsnider","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B35-20250825","article-title":"Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States","author":"Reifsnider","journal-title":"Diabetes Obes Metab"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.ajkd.2016.11.013","article-title":"Kidney disease population health management in the era of accountable care: A conceptual framework for optimizing care across the CKD spectrum","volume":"70","author":"Mendu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2016.05.029","article-title":"Electronic consultations in nephrology: Pilot implementation and evaluation","volume":"68","author":"Mendu","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2215\/CJN.02690320","article-title":"Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease","volume":"15","author":"Li","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B39-20250825","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0897190019876499","article-title":"A pilot study embedding clinical pharmacists within an interprofessional nephrology clinic for the initiation and monitoring of empagliflozin in diabetic kidney disease","volume":"34","author":"Triantafylidis","year":"2019","journal-title":"J Pharm Pract"},{"key":"B40-20250825","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2215\/CJN.05450421","article-title":"Advancing American kidney health and the role of sodium-glucose cotransporter-2 inhibitors: A missed opportunity","volume":"16","author":"Li","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41-20250825","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1717250","article-title":"A cluster-randomized trial of blood-pressure reduction in black barbershops","volume":"378","author":"Victor","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0007862021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:01:50Z","timestamp":1786478510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0007862021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0007862021","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2021-12-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}